Scientific Advisory Board

Andreeff

Michael Andreeff, M.D., Ph.D.

Michael Andreeff is Professor of Medicine, Chief, Section of Molecular Hematology and Therapy, and holds the Paul and Mary Haas Chair in Genetics at MD Anderson Cancer Center. He is an international leader in the area of malignant hematology and experimental therapeutics. Dr. Andreeff received his medical degree and doctorate from the University of Heidelberg, Germany, and additional training and faculty appointments at the Memorial Sloan-Kettering Cancer Center (MSKCC) in New York in the Departments of Pathology and Leukemia. Dr. Andreeff has been a pioneer in flow cytometry since 1971, when he established the first flow cytometry laboratory at the University of Heidelberg and organized the first European conference on flow cytometry. In 1977 he joined Memorial Sloan-Kettering Cancer Center, became head of the Leukemia Cell Biology and Hematopathology flow cytometry laboratory, organized the first Clinical Cytometry Conference in 1986 and the first Molecular Cytogenetics Conference in 1990. He has received uninterrupted NCI funding for over 30 years including as PI of SPORE, P01, R01 and R21 grants in the area of leukemia and lymphoma. He has published over 450 peer-reviewed papers, 5 books and 75 book chapters. Dr. Andreeff’s group has worked extensively on drug resistance in hematopoietic malignancies and breast cancer and developed or co-developed several new therapeutic agents including the novel triterpenoids CDDO and CDDO-Me and Bcl-2, XIAP, survivin, MEK and HDM2 inhibitors. Over the last decade, his group has made major contributions to the understanding of micro-environment-mediated drug resistance and developed strategies to exploit the underlying mechanisms for the treatment of hematopoietic and epithelial malignancies.

Keith Flaherty, M.D.

Keith Flaherty is the Director of Developmental Therapeutics at the Massachusetts General Hospital Cancer Center. He is internationally known for expertise in clinical and translational research directed against signal transduction pathways in melanoma. Dr. Flaherty earned his Bachelor of Science degree from Yale University and his MD degree from the Johns Hopkins University School of Medicine. He trained in internal medicine at the Brigham and Women’s Hospital and completed a fellowship in medical oncology at the University of Pennsylvania School of Medicine. Dr. Flaherty joined the faculty of the School of Medicine at the University of Pennsylvania as an Assistant Professor of Medicine and member of the Developmental Therapeutics Program in the Abramson Cancer Center in 2002. In 2009, Dr. Flaherty moved to Massachusetts General Hospital and Harvard Medical School to serve as the Director of Developmental Therapeutics for the MGH Cancer Center. In addition to being principal investigator of numerous first-in-human clinical trials with novel targeted therapies, he is the principal investigator of two national, cooperative group trials. He served as principal investigator for the first-in-human clinical trials of the first prospectively developed selective BRAF inhibitors, RAF-265 and PLX4032. PLX4032, later commercialized as Zelboraf, emerged as the most active single-agent therapy in metastatic melanoma patients, and was approved by the FDA after being tested in a phase III trial of which Dr. Flaherty served as co-principal investigator.

Joseph Bertino, M.D.

Joseph R. Bertino is University Professor of Medicine and Pharmacology, Rutgers Robert Wood Johnson Medical School and is the Chief Scientific Officer/Medical Oncologist at the Rutgers Cancer Institute of New Jersey. He has been an American Cancer Society professor since 1976. Dr. Bertino joined the Cancer Institute of New Jersey in 2002 as associate director and was appointed Chief Scientific Officer in 2004. Prior to joining the Cancer Institute of New Jersey, Dr. Bertino served as chair of the Molecular Pharmacology and Therapeutics Program, and member and co-head of the Program in Developmental Therapy and Clinical Investigation at Memorial Sloan-Kettering Institute for Cancer Research. From 1973 to 1986, Dr. Bertino served as director of the Yale Comprehensive Cancer Center, including Director of the center and Associate Director for clinical research. Dr. Bertino has been internationally recognized for his role in finding curative treatments for leukemia and lymphoma. During his academic career, Dr. Bertino has received several awards and honors for his research accomplishments, including the Rosenthal Award from the AACR, the Karnofsky Award from the ASCO, and the ACS Society Medal of Honor. He was founding editor of the Journal of Clinical Oncology. Currently, he is associate editor for Cancer Research and Clinical Cancer Research and also the editor of the Encyclopedia of Cancer. Dr. Bertino served as president of ASCO in 1976, and president of the AACR in 1995-96. Dr. Bertino is the author and co-author of more than 400 scientific publications. His research elucidated the mechanisms of methotrexate resistance in experimental models, and in cancer patients, has helped shape optimal methotrexate administration schedules. This has provided a foundation for rational design and development of anticancer agents. His laboratory is studying the relationship between tumor suppressor gene abnormalities and drug resistance, and the use of drug resistant genes to protect bone marrow from chemotherapy toxicity. In addition to this gene therapy research, Dr. Bertino’s lab also is focusing on umbilical cord blood expansion in stem cell research.

Fahd Al-Mulla, M.D., Ph.D., FRCP

Fahd Al-Mulla is University Professor of Molecular Pathology at Kuwait University Medical School and is the Director of Genomic Medicine at Genatak, a private establishment based within Global Med Clinic in Kuwait that seeks to provide state-of-the-art genetic tests and personalized genomic-based diagnostics. Prior to joining Genatak, Dr. Al-Mulla established a Molecular Pathology Unit at the Faculty of Medicine in Kuwait University and was appointed Director of the Research Core Facility Laboratories in Kuwait. Dr. Al-Mulla was elected as Chair to the International Confederation of Countries Advisory Council of the Human Variome Project. He received his M.D. and Ph.D. from Glasgow University and is a Fellow of the Royal College of Physicians of Edinburgh. Fahd Al-Mulla has extensive experience in technology and intellectual property development. He established the office for Technology Transfer and Patenting in Kuwait University. As an author for Nature’s Biotechnology blog, his mandate is to build collaborative partnerships, generate capital and resources, and promote public awareness regarding the importance of scientific research in resolving Arab society’s health problems and in expediting the development process. Dr. Al-Mulla’s research elucidated subtle mechanisms of cancer metastasis. His extensive research led to the identification of two novel metastasis suppressors, namely Carbonyl Reductase and Raf Kinase Inhibitory Protein, which he and his team characterized further and patented for their therapeutic roles in cancer. His laboratory is in the process of identifying novel genes involved in colon and breast cancer development and progression. Dr. Al-Mulla’s lab also is focusing on wound healing and stem cell research. Dr. Al-Mulla has spearheaded and initiated the ‘Genome Arabia’ project, which is a new technological milestone aiming at whole genome sequencing of normal Arab individuals from Kuwait, Qatar, Bahrain, UAE, and Lebanon and is funded by Qatar National Research Fund.

Ronald Landes, M.D. 

Ronald Landes is founder and president of Landes Bioscience, publisher of over 40 peer-reviewed science journals covering both basic and applied molecular biology. He is also an international investor in early-stage bioscience technology with a portfolio that includes medical devices, digital signal processing applications and drug and vaccine development. He serves on the Board of Directors for several companies and organizations, including MedicAlgorithmics in Warsaw, a provider of a cardiac monitoring device currently in wide use in the U.S.; the International Virtual eHospital, a U.S.-based non-profit; the Islet Society; the U.S. Neurobiology Society; and 700 for Science, a global nonprofit organization fostering useful connections among research scientists, strategic industry leaders and early stage investors in biotech and cleantech projects. Dr. Landes earned a BS in biochemistry from the University of Chicago, studied medicine at the Medical College of Wisconsin and trained in surgery at the University of Minnesota.